ArticleJournal of psychosocial oncology research and practice
Radioactive Iodine Symptom Burden, Psychosocial Factors, and Health-related Quality of Life among Differentiated Thyroid Cancer Survivors: A Cross-Sectional Analysis.
Article in Journal of psychosocial oncology research and practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Few studies have examined whether specific symptoms following radioactive iodine (RAI) treatment are associated with worse health-related quality of life (HRQOL) among patients with differentiated thyroid cancer (DTC), a population that is understudied in cancer survivorship research. More specifically, the relationship between RAI symptom burden and holistic HRQOL measures has not yet been evaluated in this population. This study aimed to 1) evaluate the correlation between a comprehensive patient-reported RAI symptom measure, the SAlivary, LAcrimal, and NaSal measure (SALANS), and HRQOL (FACT-G7) in patients with DTC post-RAI and 2) evaluate the relationships between HRQOL, RAI symptom burden, and psychosocial factors among patients treated with RAI for DTC. Methods: We recruited participants through a national thyroid cancer patient organization to complete an exploratory cross-sectional online survey. Pearson's correlation coefficients were used to evaluate the associations between the FACT-G7 and SALANS. Hierarchical linear regression models were used to assess the associations between HRQOL, patient-reported RAI symptom burden, and psychosocial factors, controlling for demographic and clinical factors. We used t-tests to identify variables related to clinically meaningful decreases in HRQOL. Results: Sixty-nine patients (mean age = 40.4 years, SD=14.48) who received RAI treatment (M=1.0, SD= .78) within three years of diagnosis (M=1.4, SD=.77) completed an online survey. Statistically significant moderate negative correlations were found between the RAI symptom burden scales and HRQOL ( Conclusions: Greater RAI symptom burden, distress, and lower self-efficacy were associated with worse HRQOL among patients with DTC after RAI treatment. Identifying treatment- and psychosocial-related risk factors for worse HRQOL could help identify future targets for thyroid cancer survivorship care and patients who may benefit from supportive interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.